A detailed history of Sierra Summit Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Sierra Summit Advisors LLC holds 23,075 shares of GILD stock, worth $2.57 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares
23,075
Previous 13,770 67.57%
Holding current value
$2.57 Million
Previous $1.15 Billion 84.62%
% of portfolio
0.43%
Previous 0.27%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$83.95 - $97.9 $781,154 - $910,959
9,305 Added 67.57%
23,075 $2.13 Billion
Q3 2024

Nov 13, 2024

BUY
$66.59 - $83.99 $157,285 - $198,384
2,362 Added 20.7%
13,770 $1.15 Billion
Q2 2024

Aug 09, 2024

BUY
$63.15 - $72.88 $720,415 - $831,415
11,408 New
11,408 $783 Million
Q4 2023

Feb 22, 2024

BUY
$73.27 - $83.09 $212,483 - $240,961
2,900 New
2,900 $235 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $140B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Sierra Summit Advisors LLC Portfolio

Follow Sierra Summit Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sierra Summit Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sierra Summit Advisors LLC with notifications on news.